Fresh from the Pipeline | Published:

Plerixafor

Nature Reviews Drug Discovery volume 8, pages 105107 (2009) | Download Citation

Abstract

In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & The use of growth factors in hematopoietic stem cell transplantation. Curr. Pharm. Des. 14, 1950–1961 (2008).

  2. 2.

    et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. Oncol. 13, 2547–2555 (1995).

  3. 3.

    & Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp. Hematol. 30, 973–981 (2002).

  4. 4.

    The bicyclam AMD3100 story. Nature Rev. Drug Discov. 2, 581–587 (2003).

  5. 5.

    et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728–2730 (2003).

  6. 6.

    Drug Administration. FDA labelling information. FDA web site , (2008).

  7. 7.

    et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307–1318 (2005).

  8. 8.

    et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 106, 4002–4008 (2005).

  9. 9.

    et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22, 1095–1102 (2004).

  10. 10.

    et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106, 1867–1874 (2005).

  11. 11.

    et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol. Blood Marrow Transpl. 14, 1045–1056 (2008).

  12. 12.

    et al. A Phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abs. 110, 445 (2007).

  13. 13.

    et al. A Phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abs. 110, 601 (2007).

  14. 14.

    et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor)+G-CSF for patients who failed primary mobilization: results from the Phase III (3101-NHL) study. ASH Annual Meeting Abs. 110, 602 (2007).

  15. 15.

    et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transpl. 41, 331–338 (2008).

  16. 16.

    IMS MIDAS (2007).

  17. 17.

    Wachovia Equity Research Report. (Wachovia Capital Markets, 9 Dec 2008).

  18. 18.

    Oppenheimer Equity Research Report. (Oppenheimer and Co., 3 Dec 2008).

Download references

Author information

Affiliations

  1. John F. DiPersio and Geoffrey L. Uy are at the Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA.

    • John F. DiPersio
    •  & Geoffrey L. Uy
  2. Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.

    • Uma Yasothan
  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.  jdipersi@im.wustl.edu; UYasothan@de.imshealth.com; p.kirkpatrick@nature.com

    • Peter Kirkpatrick

Authors

  1. Search for John F. DiPersio in:

  2. Search for Geoffrey L. Uy in:

  3. Search for Uma Yasothan in:

  4. Search for Peter Kirkpatrick in:

Competing interests

J.F.D and G.L.U. have received honoraria and research support from Genzyme Corporation.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd2819

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing